Researchers have developed a model for predicting risk of recurrence in early stage colon cancer patients, and have used the model to also predict sensitivity to chemotherapy and targeted therapy regimens.
Genomic Signature Of Colon Cancer May Individualize TreatmentCourtesy ScienceDaily Tue, 12/02/2008 - 17:30
Researchers have developed a model for predicting risk of recurrence in early stage colon cancer patients, and have used the model to also predict sensitivity to chemotherapy and targeted therapy regimens. More related itemsIntense Chemotherapy Wards Off Recurrence In Half Of...
Common Vitamin And Other Micronutrient Supplements...
Ovarian Cancer Stem Cells Identified, Characterized
HP 50g Graphing Calculator (F2229AA#ABA)
Kitchen Mysteries: Revealing the Science of Cooking...
|
Post new comment